Journals / İzmir Dr. Behçet Uz Çocuk Hastanesi Dergisi / 2021 / Cilt: 11 - Sayı: 1

Neuroblastoma and Hippo Signaling Pathway

Nöroblastom ve Hippo Sinyal Yolağı

Pages
1–8
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In recent studies, YAP inhibition has been shown to impair tumor growth and NB’s cisplatin resistance.This defines YAP as a potential therapeutic target, especially for cisplatin-resistant NB.Hippo is a new glimmer of hope for NB in the signal pathway and open to study and development since all steps cannot be actively determined.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Neuroblastoma (NB) is a malignant tumor often seen in early childhood and originating from the sympathetic nervous system.Hippo signal pathway is a mechanism involved in organ growth, differentiation and plays an important role in stem cells, cancer stem cells and tumorigenesis.YAP,which is the transcription co-activator, is an important part of this mechanism and the inhibition effect of YAP inhibition on cell proliferation highlights the effect of this pathway on cancer.
📊
Key Findings & Data:Along with the clinical features that affect the progression of the NB, chromosomal abnormalities and both oncogenes and tumor suppressor genes need to be evaluated together to develop new treatment strategies, especially in aggressive NB’s.
💡
Conclusion & Impact:In recent studies, YAP inhibition has been shown to impair tumor growth and NB’s cisplatin resistance.This defines YAP as a potential therapeutic target, especially for cisplatin-resistant NB.Hippo is a new glimmer of hope for NB in the signal pathway and open to study and development since all steps cannot be actively determined.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Neuroblastoma (NB) is a malignant tumor often seen in early childhood and originating from the sympathetic nervous system.Hippo signal pathway is a mechanism involved in organ growth, differentiation and plays an important role in stem cells, cancer stem cells and tumorigenesis.YAP,which is the transcription co-activator, is an important part of this mechanism and the inhibition effect of YAP inhibition on cell proliferation highlights the effect of this pathway on cancer. In the diagnosis and prognosis of pediatric tumors, more beneficial clinical applications of YAP and other routes can be considered and further research can be expected.Hippo pathway members, especially YAP, are potential new treatment targets for tumors that show overexpression. Along with the clinical features that affect the progression of the NB, chromosomal abnormalities and both oncogenes and tumor suppressor genes need to be evaluated together to develop new treatment strategies, especially in aggressive NB’s. In recent studies, YAP inhibition has been shown to impair tumor growth and NB’s cisplatin resistance.This defines YAP as a potential therapeutic target, especially for cisplatin-resistant NB.Hippo is a new glimmer of hope for NB in the signal pathway and open to study and development since all steps cannot be actively determined.

Özet

Nöroblastom (NB) sıklıkla erken çocukluk döneminde görülen ve sempatik sinir sisteminden kaynaklanan malign bir tümördür. Hippo sinyal yolağı, organ büyümesi, farklılaşması ile ilgili bir mekanizmadır ve kök hücreler, kanser kök hücreleri ve tümör oluşumunda önemli bir rol oynar. Transkripsiyon aktivatör olan YAP, bu mekanizmanın önemli bir parçasıdır ve YAP inhibisyonunun hücre çoğalması üzerindeki inhibisyon etkisi, bu yolun kanser üzerindeki etkisini vurgular.Pediatrik tümörlerin tanı ve prognozunda YAP’ın ve diğer yolların daha faydalı klinik uygulamaları düşünülebilir ve daha fazla araştırma beklenebilir. Hippo yolu üyeleri, özellikle YAP, aşırı ekspresyon gösteren tümörler için potansiyel yeni tedavi hedefleridir. NB’nin ilerlemesini etkileyen klinik özelliklerin yanı sıra, özellikle agresif NB’lerde yeni tedavi stratejileri geliştirmek için kromozomal anormalliklerin ve hem onkogenlerin hem de tümör baskılayıcı genlerin birlikte değerlendirilmesi gerekir. Son çalışmalarda YAP inhibisyonunun tümör büyümesini ve NB’nin sisplatin direncini bozduğu gösterilmiştir. YAP’ın özellikle sisplatine dirençli NB için potansiyel bir terapötik hedef olarak tanımlar. Hippo, sinyal yolunda NB için yeni bir umut ışığıdır ve tüm adımlar aktif olarak belirlenemediği için çalışmaya ve gelişmeye açıktır.

🔖

Cite This Article

ALTUN, Z., OLGUN, N., ÖZŞENGEZER, S. K. (2022). Neuroblastoma and Hippo Signaling Pathway. İzmir Dr. Behçet Uz Çocuk Hastanesi Dergisi, Cilt: 11 - Sayı: 1, 1–8. https://ajindex.com/articles/557645

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Aygun N. Biological and Genetic Features of Neuroblastoma and Their Clinical Importance. Current Pediatric Reviews. 2018, 14, 00-00.
  2. Olgun N. Türk Pedi̇atri̇k Onkoloji̇ Grubu (Tpog) Nöroblastom -2009 Tedavi̇ Protokolü 3. Cecen E, Ince D, Olgun N. Soft tissue sarcomas and central nervous system tumors in children with neurofibromatosis type 1. Child’s Nervous System. 2011;27(11):1885-93.
  3. Gatta G, Ferrari A, Stiller CA, et al. Embryonal cancers in Europe. Eur J Cancer 2012;48(10):1425-33.
  4. Ward E, DeSantis C, Robbins A, et al. Childhood and adolescent cancer statistics. CA Cancer J Clin. 2014;64(2):83-103.
  5. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11(8):1466- 77.
  6. Monclair T, Brodeur GM, Ambros PF, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009;27(2):298-303.
  7. Greengard EG. Molecularly Targeted Therapy for Neuroblastoma. Children. 2018;5:142.
  8. Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma. Lancet. 2007;369:2106-20.
  9. Tomolonis JA, Agarwal S, Shohet JM. Neuroblastoma pathogenesis: deregulation of embryonic neural crest development. Cell Tissue Res. 2018 May; 372(2):245-62.
  10. Louis CU, Shohet JM. Neuroblastoma: Molecular Pathogenesis and Therapy. Annu Rev Med. 2015;66:49-63.
  11. Baggiolini A, Varum S, Mateos JM, et al. Premigratory and migratory neural crest cells are multipotent in vivo. Cell Stem Cell. 2015;16:314-322.
  12. Pugh TJ, Morozova O, Attiyeh EF, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013; 45:279-284. [PubMed: 23334666] 14. Huang M, Weiss WA. Neuroblastoma and MYCN. Cold Spring Harb Perspect Med. 2013;3:a014415.
  13. Westermann F, Muth D, Benner A, et al. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas